Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous corneal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate

Next Previous
Drug Profile

Autologous corneal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate

Alternative Names: GPLSCD-01; Holoclar; Limbal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate; Living tissue equivalent - Chiesi/Holostem Terapie Avanzate

Latest Information Update: 14 Jun 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi; Holostem Terapie Avanzate
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Limbal stem cell deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Limbal stem cell deficiency

Most Recent Events

  • 12 Jun 2018 Launched for Limbal stem cell deficiency in Ireland and United Kingdom (Ophthalmic)
  • 12 Jun 2018 Autologous corneal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate receives Orphan Drug status for Limbal stem cell deficiency in USA
  • 05 Sep 2017 Autologous corneal epithelial stem cell therapy is still registered for Limbal stem cell deficiency in European Union, Norway, Iceland and Liechtenstein (Opthalmic) (Chiesi pipeline, September 2017)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top